Cholesterol pill tested as shield against liver cancer
NCT ID NCT05028829
Summary
This study is testing whether a low dose of the cholesterol-lowering drug atorvastatin (Lipitor) can reduce the risk of developing liver cancer in people who have advanced liver scarring (fibrosis or cirrhosis). About 60 adults with this high-risk condition will take either the statin or a placebo pill daily for one year, followed by several years of health monitoring. The main goal is to see if the treatment lowers a specific blood test score that predicts cancer risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.